← All trials
NCT06137378
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2030
- First posted
- Nov 18, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LeipzigLead sponsor
- Julius-Maximilians UniversityCollaborator
- University of KielCollaborator
- University of RegensburgCollaborator
- University of LeipzigReponsible party - principal investigator
- University of CologneCollaborator
- University of UlmCollaborator
- University of MannheimCollaborator
- Friedrich Schiller UniversityCollaborator
- University of GoettingenCollaborator
- Technical University of MunichCollaborator
- Ernst von Bergmann HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.